[go: up one dir, main page]

EA201990851A1 - NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS - Google Patents

NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS

Info

Publication number
EA201990851A1
EA201990851A1 EA201990851A EA201990851A EA201990851A1 EA 201990851 A1 EA201990851 A1 EA 201990851A1 EA 201990851 A EA201990851 A EA 201990851A EA 201990851 A EA201990851 A EA 201990851A EA 201990851 A1 EA201990851 A1 EA 201990851A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monocyclic
ring system
bicyclic ring
new
prmt5 inhibitors
Prior art date
Application number
EA201990851A
Other languages
Russian (ru)
Inventor
Тонгфей Ву
Дирк Бремер
Лейс Беке
Ан Буккс
Гастон Станислас Марселла Дилс
Эдвард Чарльз Лосон
Ливен Мерпул
Винет Панде
Маркус Корнелис Бернардус Катарина Параде
Вим Берт Грит Схепенс
Вэймэй Сунь
Йоханнес Вильхельмус Йохн Ф. Тюринг
Марсель Вьейевуа
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201990851A1 publication Critical patent/EA201990851A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к новым аналогам карбануклеозида, замещенным моноциклической и бициклической кольцевой системой, формулы (I)где переменные имеют значения, определенные в формуле изобретения. Соединения согласно настоящему изобретению являются пригодными в качестве ингибиторов PRMT5. Кроме того, настоящее изобретение относится к фармацевтическим композициям, содержащим указанные соединения в качестве активного ингредиента, а также к применению указанных соединений в качестве лекарственного препарата.The present invention relates to new analogues of carbanucleoside substituted by a monocyclic and bicyclic ring system, formula (I) where the variables have the meanings defined in the claims. The compounds of the present invention are useful as PRMT5 inhibitors. In addition, the present invention relates to pharmaceutical compositions containing said compounds as an active ingredient, and also to the use of said compounds as a medicine.

EA201990851A 2017-02-24 2017-10-02 NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS EA201990851A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17157785 2017-02-24
PCT/EP2017/074983 WO2018065365A1 (en) 2016-10-03 2017-10-02 Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors

Publications (1)

Publication Number Publication Date
EA201990851A1 true EA201990851A1 (en) 2019-09-30

Family

ID=58158964

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990851A EA201990851A1 (en) 2017-02-24 2017-10-02 NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS

Country Status (2)

Country Link
EA (1) EA201990851A1 (en)
WO (1) WO2018065365A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI791251B (en) 2015-08-26 2023-02-01 比利時商健生藥品公司 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
UA123637C2 (en) 2016-03-10 2021-05-05 Янссен Фармацевтика Нв SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
US11098062B2 (en) 2016-10-03 2021-08-24 Janssen Pharmaceutica Nv Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
MX2019010150A (en) 2017-02-27 2019-10-21 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor.
UA126481C2 (en) 2017-08-09 2022-10-12 Прел'Юд Терап'Ютікс, Інкорпорейтід Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2019084470A1 (en) * 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
SG11202005112TA (en) * 2017-12-05 2020-06-29 Angex Pharmaceutical Inc Heterocyclic compounds as prmt5 inhibitors
ES2978117T3 (en) 2017-12-08 2024-09-05 Janssen Pharmaceutica Nv New spirobicyclic analogues
PE20211444A1 (en) * 2017-12-13 2021-08-05 Lupin Ltd BICYCLE HETEROCYCLIC COMPONENTS REPLACED AS PRMT5 INHIBITORS
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
DK3765461T3 (en) 2018-03-14 2023-11-20 Prelude Therapeutics Inc SELECTIVE PROTEIN ARGININE METHYL TRANSFERASE 5 (PRMT5) INHIBITORS
AU2019317549A1 (en) * 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
GB201819621D0 (en) 2018-11-30 2019-01-16 Sumitomo Chemical Co Photoactive compound
EP3947387B1 (en) * 2019-03-25 2024-10-23 California Institute Of Technology Prmt5 inhibitors and uses thereof
BR112021019465A8 (en) 2019-04-02 2022-06-07 Aligos Therapeutics Inc Compounds that target prmt5
EP3947390A4 (en) * 2019-04-03 2022-11-30 Mitokinin, Inc. COMPOSITIONS AND METHOD OF USE THEREOF FOR TREATING NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
KR20220016194A (en) * 2019-05-30 2022-02-08 앤젝스 파마수티컬, 인크. Heterocyclic compounds as PRMT5 inhibitors
TW202112375A (en) 2019-06-06 2021-04-01 比利時商健生藥品公司 Methods of treating cancer using prmt5 inhibitors
ES2967457T3 (en) 2019-06-10 2024-04-30 Lupin Ltd PRMT5 inhibitors
AU2020290672A1 (en) 2019-06-12 2022-02-10 Janssen Pharmaceutica Nv Novel spirobicyclic intermediates
JP2022553077A (en) * 2019-10-21 2022-12-21 アクセント・セラピューティクス・インコーポレイテッド METTL3 modulator
PE20221154A1 (en) * 2019-10-22 2022-07-18 Lupin Ltd PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS
MX2022006735A (en) 2019-12-03 2022-07-21 Lupin Ltd Substituted nucleoside analogs as prmt5 inhibitors.
WO2021202480A1 (en) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Compounds targeting prmt5
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025049624A1 (en) * 2023-08-29 2025-03-06 Purdue Research Foundation Prodrugs of nicotinamide n-methyltransferase (nnmt) inhibitors and uses thereof
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
AU2003223237C1 (en) 2002-02-19 2009-03-26 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
RU2013130253A (en) 2010-12-03 2015-01-10 Эпизайм, Инк. 7-DEAZAPURINE HISTONIC METHYL TRANSFERASES AND WAYS OF THEIR APPLICATION
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CA2894228C (en) 2012-12-21 2021-08-17 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505002A (en) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド PRMT5 inhibitors containing dihydroisoquinoline or tetrahydroisoquinoline and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
UA118315C2 (en) 2015-02-24 2018-12-26 Пфайзер Інк. Substituted nucleoside derivatives useful as anticancer agents
TWI791251B (en) 2015-08-26 2023-02-01 比利時商健生藥品公司 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors

Also Published As

Publication number Publication date
WO2018065365A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
EA201990851A1 (en) NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS
EA201890573A1 (en) NEW 6-6-BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR APPLICATION AS PRMT5 INHIBITORS
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
EA202090486A2 (en) COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY
EA201891103A1 (en) COMPOSITIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201692003A1 (en) MACROCYCLIC DERIVATIVES OF PYRIMIDINE
EA201992126A1 (en) JAK INHIBITORS CONTAINING 4-MEMBER HETEROCYCLIC AMIDE
EA201892734A1 (en) AZABENZIMIDAZOLE DERIVATIVES AS AN INTEGRATOR OF pI3K BETA INHIBITORS
EA201790389A1 (en) PYRROPYRIMIDINE COMPOUNDS USED AS AN AGLIST TLR7
EA201691302A1 (en) NEW HETEROCYCLIC COMPOUNDS
EA202090688A1 (en) BIS-AMIDE CONNECTIONS ACTIVATING SARCOMER AND VARIANTS OF THEIR APPLICATION
EA201692000A1 (en) MACROCYCLIC DERIVATIVES OF PYRIDINE
EA202190960A1 (en) CONDENSED PYRROLINES THAT ACT AS INHIBITORS OF UBIKVITIN SPECIFIC PROTEASE 30 (USP30)
MX2020005944A (en) Novel spirobicyclic analogues.
EA202091256A1 (en) NEW ANTAGONISTS OF THE BRADIKININ RECEPTOR
EA201791896A1 (en) DESATECOXITUBULIZIN H AND ITS ANALOGUES
EA201890906A1 (en) DERIVATIVES OF CHINOXALINE AND PYRIDOPYRASINE AS PI3Kβ INHIBITORS
EA201792425A1 (en) TRICYCLIC COMPOUNDS AND THEIR APPLICATION AS PHOSPHODYSTERASE INHIBITORS
EA202090500A1 (en) CRYSTALLINE FORMS OF IMMUNOMODULATORS
EA202091400A1 (en) PYRROLE DERIVATIVES AS ACC INHIBITORS
EA201890534A1 (en) NEW ANNELED PHENOXYCETAMIDES
EA201691962A1 (en) AMIDOSED NITROGEN COMPOUNDS AS TNKS1 AND / OR TNKS2 INHIBITORS
EA201791396A1 (en) DERIVATIVES OF IMIDAZOPIRIDAZIN AS PI3Kβ INHIBITORS
EA202191378A1 (en) ACTIVE ESTER DERIVATIVES OF TESTOSTERONE, THEIR COMPOSITIONS AND APPLICATIONS